Tentative PDL Classes Scheduled For Review At Oct. 2024 DUR Board Meeting Announced

August 8, 2024

The following drugs and drug classes are tentatively scheduled for review during the Oct. 25, 2024, Texas Drug Utilization Review Board meeting.

Drug Classes

Androgenic Agents, topical
Antibiotics, gastrointestinal
Antibiotics, topical
Antibiotics, vaginal
Anticonvulsants
Antiemetic-Antivertigo Agents (Excludes Injectables)
Antifungals, oral
Antifungals, topical
Antihistamines, First Generation
Antiparasitics, topical
Antivirals, topical
Bone Resorption Suppression and Related Agents
Colony Stimulating Factors
Epinephrine, self-injected
GI Motility, chronic
Growth Hormone
HIV/AIDS
Hypoglycemics, incretin mimetics/enhancers
Hypoglycemics, insulin and related
Hypoglycemics, meglitinides
Hypoglycemics, metformin
Hypoglycemics, SGLT2
Hypoglycemics, TZD
Macrolides-Ketolides
Opiate Dependence Treatments
Tetracyclines

Single Drugs / PDL Classes

Cyltezo(CF) 40 mg/0.4ml syringe / Cytokine and CAM Antagonists
Cyltezo(CF) 40mg/0.4ml pen / Cytokine and CAM Antagonists
Adalimumab-adbm(CF) 40 mg syrg / Cytokine and CAM Antagonists
Adalimumab-adbm(CF) 40mg pen / Cytokine and CAM Antagonists
Omvoh syringe / Cytokine and CAM Antagonists
Rinvoq LQ / Cytokine and CAM Antagonists
Myhibbin / Immunosuppressives, Oral/SQ
Adbry autoinjector / Immunomodulators, Atopic Dermatitis
Xolair autoinjector / Immunomodulators, Asthma
Ingrezza sprinkle cap / Movement Disorders
Ojemda / Oncology, Oral- Other
Entresto sprinkle pellet / Angiotensin Modulators
Iqirvo / Bile Salts